ATE538389T1 - Test zum nachweis natriuretischer peptid- prohormone des atriums und gehirns - Google Patents

Test zum nachweis natriuretischer peptid- prohormone des atriums und gehirns

Info

Publication number
ATE538389T1
ATE538389T1 AT04740371T AT04740371T ATE538389T1 AT E538389 T1 ATE538389 T1 AT E538389T1 AT 04740371 T AT04740371 T AT 04740371T AT 04740371 T AT04740371 T AT 04740371T AT E538389 T1 ATE538389 T1 AT E538389T1
Authority
AT
Austria
Prior art keywords
natriuretic peptide
brain
atrium
test
detecting
Prior art date
Application number
AT04740371T
Other languages
English (en)
Inventor
Olli Vuolteenaho
Minna Ala-Kopsala
Heikki Ruskoaho
Juhani Leppaeluoto
Jouko Haapalahti
Original Assignee
Orion Diagnostica Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Diagnostica Oy filed Critical Orion Diagnostica Oy
Application granted granted Critical
Publication of ATE538389T1 publication Critical patent/ATE538389T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
AT04740371T 2003-06-30 2004-06-28 Test zum nachweis natriuretischer peptid- prohormone des atriums und gehirns ATE538389T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0315291A GB2403533A (en) 2003-06-30 2003-06-30 Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
PCT/EP2004/006971 WO2005003764A2 (en) 2003-06-30 2004-06-28 Assay for detecting atrial and brain natriuretic peptide prohormones

Publications (1)

Publication Number Publication Date
ATE538389T1 true ATE538389T1 (de) 2012-01-15

Family

ID=27676371

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04740371T ATE538389T1 (de) 2003-06-30 2004-06-28 Test zum nachweis natriuretischer peptid- prohormone des atriums und gehirns

Country Status (14)

Country Link
US (3) US8283123B2 (de)
EP (1) EP1664769B1 (de)
JP (1) JP4741485B2 (de)
AT (1) ATE538389T1 (de)
AU (1) AU2004254028B2 (de)
CA (1) CA2530623C (de)
DK (1) DK1664769T3 (de)
ES (1) ES2377122T3 (de)
GB (1) GB2403533A (de)
NO (1) NO339026B1 (de)
PL (1) PL1664769T3 (de)
PT (1) PT1664769E (de)
SI (1) SI1664769T1 (de)
WO (1) WO2005003764A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1731910A1 (de) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Gebrauch von NT-proANP und NT-proBNP für die Diagnose von Herzkrankheiten
WO2007003594A1 (en) * 2005-07-01 2007-01-11 Solvay Pharmaceuticals Gmbh Screening methods for inhibitors of the metalloprotease meprin
MX2009000914A (es) * 2006-08-04 2009-06-18 Hannover Med Hochschule Medios y metodos para evaluar el riesgo de intervenciones cardiacas basadas en el factor 15 de diferenciacion del crecimiento.
ATE449966T1 (de) 2006-09-15 2009-12-15 Hoffmann La Roche Biochemische marker für akute lungenembolie
EP2180322A1 (de) 2008-10-22 2010-04-28 BRAHMS Aktiengesellschaft Prognostische Biomarker zur Progression von primär chronischen Nierenerkrankungen
WO2010065293A1 (en) 2008-12-03 2010-06-10 Boehringer Ingelheim Pharmaceuticals Inc. Antibodies for guanylyl cyclase receptors
JP5753159B2 (ja) * 2009-05-05 2015-07-22 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 内皮性機能／機能不全に関連した疾患に罹患している患者の血管作動性ホルモンに基づいた層化
JP5362487B2 (ja) * 2009-08-27 2013-12-11 塩野義製薬株式会社 ｐｒｏＢＮＰ−１０８の新規用途
US9018168B2 (en) 2010-08-12 2015-04-28 Madeleine Pharmaceuticals Pty Ltd Therapeutic method for treating congestive heart failure
MX353295B (es) 2011-01-21 2018-01-08 Endo Kyoko Agente para el tratamiento de la alopecia.
WO2014138796A1 (en) 2013-03-15 2014-09-18 Madeleine Pharmaceuticals Pty Ltd Dosage regimen for therapeutic method
WO2015135024A1 (en) 2014-03-14 2015-09-17 Madeleine Pharmaceuticals Pty Ltd Adjuvant therapy to standard of care (soc) diuretic treatment
WO2017161327A1 (en) * 2016-03-17 2017-09-21 Diazyme Laboratories, Inc. Use of fusion proteins to improve the availability of antigenic peptide epitopes in immunoassays
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
KR20220009440A (ko) * 2019-05-19 2022-01-24 미요카디아, 인크. 화합물 (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드를 사용한 수축기 기능장애 및 감소된 박출 계수를 가진 심부전의 치료
GB2621544A (en) * 2022-07-07 2024-02-21 Biohabit Ltd Methods of detecting a disease or condition
CN117285624B (zh) * 2023-09-28 2024-04-26 北京达成生物科技有限公司 抗犬NT-proBNP双特异性抗体及试剂盒

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212286A (en) * 1984-04-19 1993-05-18 Scios Nova Inc. Atrial natriuretic/vasodilator peptide compounds
EP0267272A4 (de) 1986-05-09 1990-03-12 Biotechnology Res Associates J Atriales natriuretisches peptid rezeptor protein und dessen dns-kodierung.
JPS6461500A (en) * 1987-09-01 1989-03-08 Shionogi & Co Alpha-hanp recognizing monoclonal antibody and immunologically measuring reagent for alpha-hanp
JPH0667319B2 (ja) 1989-04-19 1994-08-31 塩野義製薬株式会社 Ａｎｐのｃ端側を認識するモノクローナル抗体
DE69032598T2 (de) 1989-06-23 1999-03-11 Genentech, Inc., South San Francisco, Calif. Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
US5604105B1 (en) * 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
WO1995028952A1 (de) 1992-12-09 1995-11-02 Haemopep Pharma Gmbh Verwendung der brain natriuretic peptide (bnp), phosphoryliertes urodilatin, phosphoryliertes cdd/anp sowie deren kombinationen
DE69733560T2 (de) 1996-03-04 2006-05-11 Scios Inc., Fremont TESTVERFAHREN UND REAGENZIEN ZUR QUANTIFIZIERUNG VON hBNP
US6117644A (en) * 1998-06-04 2000-09-12 Ottawa Heart Institute Research Corporation Predicting and detecting cardiac allograft rejection
WO2000018422A1 (fr) 1998-09-28 2000-04-06 Santen Pharmaceutical Co., Ltd. Promoteurs de secretion lacrymale ou gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs pour traiter la keratoconjonctivite
AT407674B (de) 1998-09-29 2001-05-25 Biomedica Gmbh Verfahren zur bestimmung von atrialem natriuretischem peptid (anp)
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
PL204235B1 (pl) 1999-01-29 2009-12-31 Roche Diagnostics Gmbh Sposób wykrywania natywnego N-końcowego proBNP, zastosowanie tego sposobu, zastosowanie zrekombinowanego N-końcowego proBNP, przeciwciała przeciw zrekombinowanemu N-końcowemu proBNP, linie komórkowe i sposoby wytwarzania przeciwciał poliklonalnych i monoklonalnych
AU3609300A (en) * 1999-03-01 2000-09-21 Human Genome Sciences, Inc. Human serpin proteins
AU5043900A (en) * 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
CA2342683A1 (en) * 2000-04-03 2001-10-03 Unilever Plc Test methods and devices
AU2001255402A1 (en) * 2000-04-14 2001-10-30 Genaissance Pharmaceuticals, Inc. Haplotypes of the npr1 gene
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
US6461828B1 (en) * 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
AU2002341621A1 (en) * 2001-09-10 2003-03-24 Meso Scale Technologies, Llc Methods, reagents, kits and apparatus for protein function analysis
CN100593721C (zh) * 2001-11-27 2010-03-10 迪尔基因国际有限公司 用于病人的样本中生物化学标记物的早期和同步检测的免疫测定法和试剂盒
ATE272214T1 (de) * 2001-12-04 2004-08-15 Brahms Ag Verfahren zur diagnose von sepsis unter bestimmung von s100b
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7341838B2 (en) * 2003-04-17 2008-03-11 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use

Also Published As

Publication number Publication date
DK1664769T3 (da) 2012-03-19
PL1664769T3 (pl) 2012-06-29
ES2377122T3 (es) 2012-03-22
GB2403533A (en) 2005-01-05
US8283123B2 (en) 2012-10-09
JP2007526988A (ja) 2007-09-20
US20130157311A1 (en) 2013-06-20
NO339026B1 (no) 2016-11-07
SI1664769T1 (sl) 2012-04-30
NO20060481L (no) 2006-01-30
JP4741485B2 (ja) 2011-08-03
EP1664769B1 (de) 2011-12-21
EP1664769A2 (de) 2006-06-07
AU2004254028A1 (en) 2005-01-13
AU2004254028B2 (en) 2010-10-14
CA2530623A1 (en) 2005-01-13
PT1664769E (pt) 2012-03-09
CA2530623C (en) 2014-09-16
US20070141634A1 (en) 2007-06-21
WO2005003764A3 (en) 2006-12-14
WO2005003764A2 (en) 2005-01-13
GB0315291D0 (en) 2003-08-06
US20160084852A1 (en) 2016-03-24
US9151766B2 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
ATE538389T1 (de) Test zum nachweis natriuretischer peptid- prohormone des atriums und gehirns
AU2003288027A1 (en) Scd40l, papp-a and placental growth factor (plgf) used as a biochemical marker combination in cardiovascular diseases
NZ512762A (en) Method of identifying N-terminal proBNP (brain natriuretic peptide) using antibodies
WO2004055519A3 (en) Specific markers for pancreatic cancer
EP1625163B8 (de) Verfahren zum nachweis von probnp mit einem monoklonalen antikörper, der die amino saüre 38-43 bindet
ATE511656T1 (de) Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
MY149161A (en) Methods using pores
WO2009129454A3 (en) Predicting risk of major adverse cardiac events
ATE469353T1 (de) Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen
ATE515573T1 (de) Verfahren zum nachweis der grösse von nukleinsäuren
WO2008106938A3 (de) Diagnose und risikostratifizierung von herzinsuffizienz mittels natriuretischen peptiden für nyha i patienten
NZ576061A (en) Biomarkers
DE60025347D1 (de) Methoden zur vohersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests
ATE335763T1 (de) Sandwich-immunoassay zur bestimmung von proanp- teilpeptiden
SG11201908520TA (en) Method for simultaneous quantification of monoclonal antibodies
WO2021021964A3 (en) Methods of quantifying frataxin and frataxin fusion proteins
WO2005116660A3 (en) Methods for making and using mass tag standards for quantitative proteomics
WO2003027149A1 (fr) Anticorps et utilisation de ce dernier
FI20115367A0 (fi) Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja
CN102007415B (zh) 降钙素原(pct)在急性冠脉综合征的预后中的应用
RU2014107752A (ru) Среднерегиональный предшественник предсердного натрийуретического пептида (pro-anp) для идентификации пациентов с фибрилляцией предсердий, начавшейся меньше, чем 48 часов тому назад
UA112515C2 (uk) Спосіб виявлення присутності двох або більше білків, що становлять інтерес, в зразках рослинного походження
WO2006053251A3 (en) Method of measuring amyloid-beta peptides
WO2006002841A3 (en) Analysis method
WO2007063129A3 (en) Insolation of peptides , polypeptides and proteins